News explainer · Safety

Counterfeit Ozempic reached licensed U.S. pharmacies twice

In April 2025 and again in December 2025, the FDA seized counterfeit Ozempic that had entered the legitimate U.S. supply chain — carrying authentic lot numbers, dispensed through licensed retail pharmacies. That detail matters more than the seizures themselves: it defines what 'I bought it from a real pharmacy' can and cannot guarantee.

The two incidents

In April 2025, Novo Nordisk notified the FDA that several hundred units of Ozempic injection 1 mg had been distributed outside its authorized supply chain; the FDA seized the identified products on April 9, 2025 [1]. In December 2025, the agency seized dozens of further counterfeit units labeled with a different — also authentic — lot number [2]. In the seized products, the needles themselves were counterfeit, so their sterility could not be confirmed; the pen label, patient information, and carton were also confirmed counterfeit, and neither the FDA nor Novo Nordisk could confirm what the injected substance actually was [3].

How to identify affected product

One wrinkle, sourced to trade press rather than the FDA alert and labeled accordingly: Novo Nordisk has stated that Ozempic 1 mg obtained through its Patient Assistance Program is genuine notwithstanding the lot number [6]. If your product came through that program and you are unsure, that is a question for the pharmacy that dispensed it — not one to resolve by guesswork.

Why supply-chain penetration matters

Both confirmed incidents involved product that reached patients through licensed retail pharmacies [5]. The standard advice in this market — avoid gray-market sellers, use licensed pharmacies — remains correct and necessary, but these incidents show it is not sufficient: a licensed dispenser is a strong filter, not an absolute one. The practical consequence is that product-level checks (lot and serial identifiers against the current FDA alert) are worth doing even on legitimately dispensed pens, and that a provider or pharmacy unwilling to say where its product comes from is asking you to skip a verification step the supply chain has twice been shown to need. Our verification guide covers the checkable registers.

Reported harm

The FDA reported awareness of five adverse events from the PAR1229 lot, none serious, and all consistent with common reactions to authentic Ozempic — nausea, vomiting, diarrhea, abdominal pain, constipation [4]. That is what was reported; it is not a finding that the counterfeit product was safe. Since the drug's identity and quality could not be confirmed [3], the honest statement is that the harm profile of the counterfeit units is unknown.

What remains unknown

Where the counterfeit product entered the distribution chain; how many units were dispensed before the seizures; what substance the counterfeit pens actually contained [3]; and whether further lots are affected beyond the two identified. The FDA alert is the living document here — check it directly (it is linked in the source list below with its capture date) rather than relying on this page's snapshot if you are making a decision about product in hand.

If you suspect a pen you hold is counterfeit: do not use it, keep the pen, carton, and any paperwork together (the identifiers above live on them), and take the question back to the pharmacy that dispensed it — the dispenser is the party positioned to trace the unit against its own supply records, and the FDA alert linked below states how the agency wants suspected product handled and reported.